BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 29967955)

  • 1. Dynamic contrast-enhanced CT for the assessment of tumour response in malignant pleural mesothelioma: a pilot study.
    Gudmundsson E; Labby Z; Straus CM; Sensakovic WF; Li F; Rose B; Cunliffe A; Kindler HL; Armato SG
    Eur Radiol; 2019 Feb; 29(2):682-688. PubMed ID: 29967955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a comparative study of pharmacokinetic models and correlation with mRECIST criteria.
    Vivoda Tomšič M; Bisdas S; Kovač V; Serša I; Šurlan Popovič K
    Cancer Imaging; 2019 Feb; 19(1):10. PubMed ID: 30813957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma.
    Kanemura S; Kuribayashi K; Funaguchi N; Shibata E; Mikami K; Doi H; Kitajima K; Hasegawa S; Nakano T
    Eur J Radiol; 2017 Jan; 86():92-98. PubMed ID: 28027772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of response classification criteria for patients with malignant pleural mesothelioma, a validation study.
    Buikhuisen WA; Qayyum F; Armato SG; Baas P
    Lung Cancer; 2019 Dec; 138():139-140. PubMed ID: 31733933
    [No Abstract]   [Full Text] [Related]  

  • 5. 18F-Fluorodeoxyglucose PET/CT and dynamic contrast-enhanced MRI as imaging biomarkers in malignant pleural mesothelioma.
    Hall DO; Hooper CE; Searle J; Darby M; White P; Harvey JE; Braybrooke JP; Maskell NA; Masani V; Lyburn ID
    Nucl Med Commun; 2018 Feb; 39(2):161-170. PubMed ID: 29300270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1).
    Armato SG; Nowak AK
    J Thorac Oncol; 2018 Jul; 13(7):1012-1021. PubMed ID: 29753121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CT, RECIST, and malignant pleural mesothelioma.
    Nowak AK
    Lung Cancer; 2005 Jul; 49 Suppl 1():S37-40. PubMed ID: 15950799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.
    van Zandwijk N; Pavlakis N; Kao SC; Linton A; Boyer MJ; Clarke S; Huynh Y; Chrzanowska A; Fulham MJ; Bailey DL; Cooper WA; Kritharides L; Ridley L; Pattison ST; MacDiarmid J; Brahmbhatt H; Reid G
    Lancet Oncol; 2017 Oct; 18(10):1386-1396. PubMed ID: 28870611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging in pleural mesothelioma: A review of the 13th International Conference of the International Mesothelioma Interest Group.
    Armato SG; Blyth KG; Keating JJ; Katz S; Tsim S; Coolen J; Gudmundsson E; Opitz I; Nowak AK
    Lung Cancer; 2016 Nov; 101():48-58. PubMed ID: 27794408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group.
    Laurie SA; Hao D; Leighl NB; Goffin J; Khomani A; Gupta A; Addison CL; Bane A; Seely J; Filion ML; Pond GR; Levine MN
    Lung Cancer; 2017 Feb; 104():65-69. PubMed ID: 28213002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma.
    Nowak AK; Brown C; Millward MJ; Creaney J; Byrne MJ; Hughes B; Kremmidiotis G; Bibby DC; Leske AF; Mitchell PLR; Pavlakis N; Boyer M; Stockler MR
    Lung Cancer; 2013 Sep; 81(3):422-427. PubMed ID: 23787063
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Niccoli Asabella A; Di Palo A; Altini C; Fanelli M; Ferrari C; Lavelli V; Ranieri G; Gadaleta CD; Rubini G
    Hell J Nucl Med; 2018; 21(3):191-197. PubMed ID: 30411729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of metabolic response by positron emission tomography after neoadjuvant chemotherapy for resectable malignant pleural mesothelioma.
    Tsutani Y; Takuwa T; Miyata Y; Fukuoka K; Hasegawa S; Nakano T; Okada M
    Ann Oncol; 2013 Apr; 24(4):1005-10. PubMed ID: 23136224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of patient survival with clinical tumor measurements in malignant pleural mesothelioma.
    Li F; Ahmad M; Qayyum F; Straus CM; MacMahon H; Kindler H; Armato SG
    Eur Radiol; 2019 Jun; 29(6):2981-2988. PubMed ID: 30617480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic contrast-enhanced MRI in malignant pleural mesothelioma: prediction of outcome based on DCE-MRI measurements in patients undergoing cytotoxic chemotherapy.
    Vivoda Tomšič M; Korošec P; Kovač V; Bisdas S; Šurlan Popovič K
    BMC Cancer; 2022 Feb; 22(1):191. PubMed ID: 35184730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pilot study of combined FDG-PET and dynamic contrast-enhanced CT of locally advanced cervical carcinoma before and during concurrent chemoradiotherapy suggests association between changes in tumor blood volume and treatment response.
    Banks TI; von Eyben R; Hristov D; Kidd EA
    Cancer Med; 2018 Aug; 7(8):3642-3651. PubMed ID: 29963760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computer-aided volumetric assessment of malignant pleural mesothelioma on CT using a random walk-based method.
    Chen M; Helm E; Joshi N; Gleeson F; Brady M
    Int J Comput Assist Radiol Surg; 2017 Apr; 12(4):529-538. PubMed ID: 28028655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease volumes as a marker for patient response in malignant pleural mesothelioma.
    Labby ZE; Nowak AK; Dignam JJ; Straus C; Kindler HL; Armato SG
    Ann Oncol; 2013 Apr; 24(4):999-1005. PubMed ID: 23144443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of tumor response in malignant pleural mesothelioma.
    Ceresoli GL; Chiti A; Zucali PA; Cappuzzo F; De Vincenzo F; Cavina R; Rodari M; Poretti D; Lutman FR; Santoro A
    Cancer Treat Rev; 2007 Oct; 33(6):533-41. PubMed ID: 17764849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Multicenter Study of Volumetric Computed Tomography for Staging Malignant Pleural Mesothelioma.
    Rusch VW; Gill R; Mitchell A; Naidich D; Rice DC; Pass HI; Kindler HL; De Perrot M; Friedberg J;
    Ann Thorac Surg; 2016 Oct; 102(4):1059-66. PubMed ID: 27596916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.